RhoVac

RhoVac is an immunooncology company developing a novel therapeutic cancer vaccine targeting metastatic cancer cells. The cancer vaccine product RV001 is already in clinical trials, capable of identifying high concentrations of RHO cells and stimulating the immune system to target them. RhoVac's concept focuses on eliminating cancer cells with metastatic potential that evade treatment of the primary tumor through other methods. The company is headquartered in Sweden and Denmark and is listed on the Swedish stock market. RhoVac is managed and advised by a senior executive team with extensive expertise and many years of experience.